NASDAQ:NBY - NovaBay Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.55 0.00 (0.00 %) (As of 10/19/2018 04:00 PM ET)Previous Close$1.55Today's Range$1.51 - $1.5652-Week Range$1.25 - $4.80Volume3,748 shsAverage Volume12,840 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and markets anti-infective products for the eye care market in the United States. Its commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. The company has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California. Receive NBY News and Ratings via Email Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A SymbolNASDAQ:NBY CUSIPN/A Webwww.novabaypharma.com PhoneN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding Shares17,090,000Market Cap$0.00 NovaBay Pharmaceuticals (NASDAQ:NBY) Frequently Asked Questions What is NovaBay Pharmaceuticals' stock symbol? NovaBay Pharmaceuticals trades on the NASDAQ under the ticker symbol "NBY." How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NASDAQ:NBY) announced its quarterly earnings data on Tuesday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The firm had revenue of $2.79 million for the quarter, compared to the consensus estimate of $3.48 million. View NovaBay Pharmaceuticals' Earnings History. When is NovaBay Pharmaceuticals' next earnings date? NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 13th 2018. View Earnings Estimates for NovaBay Pharmaceuticals. What is the consensus analysts' recommendation for NovaBay Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals. Who are NovaBay Pharmaceuticals' key executives? NovaBay Pharmaceuticals' management team includes the folowing people: Mr. Mark M. Sieczkarek, Chairman, CEO & Pres (Age 63)Mr. Justin M. Hall, Sr. VP & Gen. Counsel (Age 40)Mr. John J. McGovern, CFO, Treasurer & Principal Accounting OfficerDr. David W. Stroman Ph.D., Sr. VP of Ophthalmic Product Devel. and Chair of Ophthalmology Advisory Board (Age 73)Mr. Lewis J. Stuart BA, MBA, Chief Commercial Officer (Age 59) How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is NovaBay Pharmaceuticals' stock price today? One share of NBY stock can currently be purchased for approximately $1.55. What is NovaBay Pharmaceuticals' official website? The official website for NovaBay Pharmaceuticals is http://www.novabaypharma.com. MarketBeat Community Rating for NovaBay Pharmaceuticals (NASDAQ NBY)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 34 (Vote Outperform)Underperform Votes: 49 (Vote Underperform)Total Votes: 83MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/20/2018 by MarketBeat.com StaffFeatured Article: How is the discount rate different from the Federal Funds rate?